Key facts
- Akura Medical’s last known valuation is $215.0M (Dec 2025).
- It has raised $113.0M across 3 recorded rounds; the latest was Later Stage VC ($51.4M) in Nov 2025.
- Notable investors include Qatar Investment Authority, Cormorant Asset Management, Lilly Asia Ventures, TCP Health Ventures, AMED Ventures — 10 tracked in total.
- Akura Medical has filed 3 Form Ds with the SEC since 2022, most recently Dec 2025 ($51.4M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Akura Medical
Funding rounds
3 roundsAbout Akura Medical
Developer of medical devices designed to offer effective and easy-to-use clot removal. The company provides thrombectomy devices, along with surgical, medical, dental, and veterinary apparatus and instruments, enabling doctors to address critical healthcare needs and treat venous thromboembolism of all sizes.
- Sector
- Healthcare
- HQ
- Los Gatos, CA, United States
- Founded
- 2019
- Employees
- 30
- Website
- akuramedical.com/
- Ownership
- Privately Held (backing)
Akura Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Akura Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Akura Medical in its N-PORT filings yet. We sweep new filings monthly.